HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

Abstract
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab-nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients' survival based on their baseline and disease characteristics.
AuthorsOlivier J van Not, Thijs T Wind, Rawa K Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, John B Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S van Rijn, Marion Stevense-den Boer, Astrid A M van der Veldt, Gerard Vreugdenhil, Michel W J M Wouters, Willeke A M Blokx, Karijn P M Suijkerbuijk, Rudolf S N Fehrmann, Geke A P Hospers
JournalCancers (Cancers (Basel)) Vol. 15 Issue 11 (May 26 2023) ISSN: 2072-6694 [Print] Switzerland
PMID37296885 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: